Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4344641 | 0.83 | OPRM1 (0.56) | OPRM1OPRL1OPRK1OPRD1CHRM2 | |
| SCHEMBL4352252 | 0.83 | OPRM1 (0.46) | OPRM1OPRL1OPRK1OPRD1DHCR7 | |
| SCHEMBL4344823 | 0.82 | OPRM1 (0.59) | OPRM1OPRL1OPRK1OPRD1CHRM2 | |
| SCHEMBL4347994 | 0.81 | OPRM1 (0.46) | OPRM1OPRL1OPRK1OPRD1CHRM2 | |
| SCHEMBL3404628 | 0.81 | OPRM1 (0.45) | OPRM1OPRL1OPRK1CHRM2CHRM4 | |
| SCHEMBL4350703 | 0.79 | OPRM1 (0.48) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL4348019 | 0.79 | OPRL1 (0.53) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL3410347 | 0.78 | OPRM1 (0.48) | OPRM1OPRL1OPRK1OPRD1CHRM2 | |
| SCHEMBL4352367 | 0.78 | OPRM1 (0.40) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3405713 | 0.77 | CHRM1 (0.51) | OPRM1OPRL1CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | CACNA1A, SCN10A, OPRM1 | OPRM1 3/4885OPRL1 4/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.